← All trials
NCT03693781
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 30, 2019
- Primary completion
- Nov 1, 2020
- Completion date
- Nov 1, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 54
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of Modena and Reggio EmiliaLead sponsor
- University of TurinCollaborator
- Vita-Salute University of Milano. ItalyCollaborator
- University of Campania Luigi VanvitelliCollaborator
- Catholic University of Sacred Heart, RomeCollaborator
- Mario Negri InstituteCollaborator
- University of Modena and Reggio EmiliaCollaborator
- University of MilanCollaborator
- University of BariCollaborator
- University of PadovaCollaborator
- University of Modena and Reggio EmiliaOverall official - principal investigator
- University of Modena and Reggio EmiliaReponsible party - principal investigator
- Istituto Auxologico ItalianoCollaborator
- IRCCS National Neurological Institute C. Mondino FoundationCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.